MYC Gene Function
MYC Proto-Oncogene, BHLH Transcription Factor
Overview
MYC is dysregulated in ~70% of human cancers through amplification (SCLC, neuroblastoma), chromosomal translocation (Burkitt lymphoma t(8;14)), or constitutive upstream RAS/WNT/PI3K signalling. As a global transcriptional amplifier, MYC drives >15% of all human genes including ribosome biogenesis, aerobic glycolysis, and cell cycle entry. The central oncogenic paradox: MYC overexpression simultaneously drives proliferation and sensitises cells to apoptosis via ARF→p53 — requiring BCL2 co-expression or TP53 loss for tumour cell survival. Direct targeting remains elusive due to its disordered structure; BET bromodomain inhibitors (OTX-2002) suppress super-enhancer-driven MYC transcription and CDK7 inhibitors block MYC target gene activation — both in clinical development.
Molecular Mechanism
Mechanism Summary
MYC dysregulation—through amplification, chromosomal translocation or sustained upstream signalling—reshapes transcriptional programmes governing ribosome biogenesis, metabolism and cell-cycle entry. MYC can also increase apoptotic stress, so tumour survival often depends on additional context such as p53-pathway disruption or anti-apoptotic signalling; no single co-mutation is mandatory. BET, CDK7 and MYC–MAX strategies are investigational approaches to MYC dependence rather than validated pan-cancer treatments.
Step-by-Step Mechanism
MYC heterodimerises with MAX via bHLH-LZ domains, forming a high-affinity complex that binds E-box motifs (CACGTG) in promoters and enhancers of target genes genome-wide.
MYC-MAX recruits the TRRAP/TIP60 and p300/CBP histone acetyltransferase complexes, promoting H3K9ac and H3K27ac marks associated with active transcription. MYC also recruits CDK8/Mediator to pause-release RNA Pol II.
MYC activates RNA Pol I transcription of ribosomal RNA genes and RNA Pol III transcription of 5S rRNA and tRNAs, massively expanding translational capacity. This ribosome biogenesis programme is a key MYC oncogenic output.
Upstream Regulators
Phosphorylates MYC Ser62, stabilising the protein; blocks GSK3β-mediated Thr58 phosphorylation
Phosphorylates Thr58 after initial Ser62 phosphorylation, targeting MYC for FBXW7-mediated ubiquitination and degradation
Transcriptionally activates MYC gene directly via TCF/LEF binding to MYC enhancer
Downstream Targets
Ribosome biogenesis; translational capacity expansion
Cell cycle entry and progression
Warburg-type aerobic glycolysis
Key Post-Translational Modifications
Stabilises MYC protein; antagonises Thr58-mediated degradation
Targets MYC for FBXW7-mediated ubiquitination and 26S proteasome degradation
Rapid proteasomal degradation; FBXW7 is frequently mutated in cancer
Disease Mechanism
MYC-family dysregulation can arise through amplification, chromosomal translocation or sustained upstream signalling. MYC is a transcription factor rather than an enzyme with a conventional catalytic pocket, so most therapeutic strategies are indirect or investigational. Approaches include disrupting MYC–MAX interactions, altering transcriptional dependencies such as BET or CDK7 activity, and targeting lineage-specific dependencies such as the Aurora-A–MYCN interaction. Evidence varies substantially by agent and tumour type; MYC amplification or expression alone is not a validated pan-cancer treatment selector.
Database References
Key Pathways
- ·Cell cycle regulation
- ·Ribosome biogenesis
- ·Warburg effect/glycolysis
- ·Wnt signaling
- ·BET bromodomain regulation
Disease Associations
- ·Burkitt lymphoma
- ·Small cell lung cancer
- ·Neuroblastoma (MYCN)
- ·Multiple myeloma
Research Activity
MYC is an actively studied target: about 40+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track MYC trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About MYC
Is MYC an oncogene?
Yes — MYC is a proto-oncogene that becomes an oncogene when overexpressed or amplified. It is a master transcription factor driving ribosome biogenesis, metabolic reprogramming, and cell cycle progression, and its dysregulation contributes to approximately 70% of human cancers in one form or another.
What does MYC do in cancer cells?
Overexpressed MYC drives a transcriptional programme that forces cells into continuous proliferation, upregulating thousands of target genes involved in metabolism, protein synthesis, and cell cycle entry. MYC also paradoxically sensitises cells to apoptosis — explaining why MYC-driven cancers require co-mutations in anti-apoptotic genes like BCL2 to survive.
What is MYCN amplification and where does it occur?
MYCN amplification is a strong adverse prognostic marker in neuroblastoma, present in ~25% of cases and associated with rapid progression and poor outcome. MYCN drives proliferation through the same transcriptional mechanisms as MYC. Amplification also occurs in small cell lung cancer, medulloblastoma, and retinoblastoma.
Can MYC be targeted by drugs?
Direct MYC inhibition has been challenging due to its intrinsically disordered structure and lack of a druggable binding pocket. Indirect approaches — including BET bromodomain inhibitors (JQ1) that suppress MYC transcription, and Aurora A inhibitors that destabilise the MYC protein — are in clinical trials.
What is MYC amplification and how does it drive cancer differently from other oncogenes?
MYC amplification produces many extra copies of the MYC gene (often as extrachromosomal DNA or tandem duplications), increasing MYC protein to levels far above normal mitogenic signalling. Unlike kinase oncogenes (EGFR, BRAF) that create a single constitutive signal, MYC hyperactivation simultaneously upregulates thousands of target genes across metabolism, ribosome biogenesis, cell cycle, and angiogenesis — essentially forcing an entire pro-tumorigenic transcriptional programme. MYC amplification is particularly prominent in small cell lung cancer (>60% of cases), neuroblastoma (MYCN, ~25%), and as a mechanism of resistance to targeted therapy (e.g., MYC amplification as acquired resistance to BRAF inhibitors in melanoma).
Why does MYC overexpression paradoxically sensitise cells to apoptosis?
This is one of the most important concepts in MYC biology: overexpressed MYC directly induces its own check through ARF (p14ARF, encoded by CDKN2A). ARF sequesters MDM2 in the nucleolus, stabilising p53, which then activates pro-apoptotic targets (BAX, PUMA, BIM). Additionally, MYC directly transcribes BIM (BCL2L11) independently of p53. The result is that MYC-driven proliferation also primes cells for cell death — requiring co-mutations in BCL2 (as in Burkitt lymphoma's frequent BCL2 translocations) or TP53 loss to allow tumour survival. This paradox is therapeutically exploitable: BH3-mimetics (venetoclax) show enhanced activity in MYC-overexpressing tumours because cells are pre-loaded with pro-apoptotic signal.
What are BET bromodomain inhibitors and how do they target MYC indirectly?
BET proteins (BRD2, BRD3 and BRD4) bind acetylated chromatin and help support transcription at enhancers and promoters. In some MYC-driven models, BET inhibition reduces enhancer-dependent MYC expression, but the effect is not exclusive to MYC and has not created a general treatment for MYC-amplified tumours. Agent, tumour lineage, target engagement and trial evidence must be evaluated separately.